Skip to main content
2022 PDTC Cover Image
Working with Us

2023 PD Therapeutics Conference

About the Conference
2022 PDTC Panel Discussion

*At this time, there are no current CDC guideline or local rules and regulations in place for COVID-19. As such, this meeting will not require proof of vaccination or testing, and while masking is encouraged, it will be optional. As the course of the pandemic shifts or local, state or federal regulations change, we will follow science and update all attendees. For international attendees, please make sure to check the rules on arrival and departure with your country and the United States. The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 15th Annual PD Therapeutics Conference is scheduled to be held on October 19, 2023, in New York.

Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Thank you for your tremendous enthusiasm for this year's event. Registration has reached its maximum capacity. We will shortly inform those who had joined the waitlist about their potential to attend.

For any questions, please contact researchmeetings@michaeljfox.org.

Conference Schedule (subject to change)
7:45
ARRIVALS & BREAKFAST
8:30-8:45
WELCOME REMARKS
Sohini Chowdhury | The Michael J. Fox Foundation
8:45-11:10
Session 1: Advances in Emerging Targets and Therapeutic Development
SESSION INTRODUCTION by Session Chair
Session Chair: Karoly Nikolich, PhD | Alkahest Inc.
GP2- Globalizing Parkinson’s Disease Genetics
Speaker: Andrew Singleton, PhD | National Institutes of Health
Transcriptomic analysis in PPMI/AMP-PD
Speaker: Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute
Identification of TMEM175 Activators as Candidate Disease-Modification Therapeutics for Parkinson Disease
Speaker: David Stone, PhD | Cerevel Therapeutics
Development of USP30 Inhibitors for Parkinson’s Disease
Speaker: Paul Thompson, PhD | Mission Therapeutics
Kv1.3 Blockade to Resolve Neuroinflammation in Parkinson's Disease
Speaker: Niels Plath, PhD | Muna Therapeutics
CLOSING REMARKS from Session Chair
Karoly Nikolich, PhD | Alkahest Inc.
10:40 - 11:10
Networking Break / Poster Viewing
11:10 - 12:20
Session 2: Advances in the Classification and Measurement of Parkinson's
SESSION INTRODUCTION by Session Chair
Kathleen Poston, MD, MS | Stanford University
Neuropathology of Lewy Body Diseases
Speaker: Tom Montine, MD, PhD | Stanford University
Biological Definition and Integrated Staging System for Neuronal Synuclein Disease: Accelerating Therapeutics for Synucleinopathy
Speaker: Kenneth Marek, MD | Institute for Neurodegenerative Disorders
Alpha-Synuclein Seed Amplification Assays: Current Utility and Future Prospects to Aid Therapeutic Development
Speaker: Kalpana Merchant, PhD | Northwestern University | TransThera Consulting Co.
12:20 - 1:25
Networking Break / Poster Viewing / Lunch
Overview of Pre-Competitive Molecular Imaging Consortium
Speaker: Jamie Eberling, PhD | The Michael J. Fox Foundation
Digital Measures in Parkinson’s Disease: WATCH-PD Study
Speaker: Jamie Adams, MD | University of Rochester
De-Risking Therapeutic Development: The Power of Mitophagy Biomarkers in PD
Speaker: Bill Shrader, PhD | AcureX
CLOSING REMARKS from Session Chair
Kathleen Poston, MD, MS | Stanford University
2:40 - 3:10
Networking Break / Poster Viewing
3:10 - 4:40
Session 3: Panel Discussions
Applying the Neuronal Synuclein Disease Integrated Staging System to Clinical Trials
Moderator: Karl Kieburtz, MD, MPH | University of Rochester; Panelists: Gennaro Pagano, MD, PhD | Roche; Tien Dam, MD | Biogen; Tanya Fischer, MD, PhD | Biohaven
Advancing the use of Patient Voice to Drive Successful R&D
Moderator: Katie Kopil, PhD | The Michael J. Fox Foundation; Panelists: Vicky DiBiaso, PhD | Sanofi; Alison Handler, PharmD, RPh | Novartis; Gary Rafaloff | MJFF Patient Council; Soania Mathur, MD | MJFF Patient Council
CLOSING REMARKS
Speaker: Sohini Chowdhury | The Michael J. Fox Foundation
4:40 - 6:00
Cocktail Reception / Poster Viewing
Speakers

Jamie Adams, MD | University of Rochester 

Tien Dam, MD | Biogen

Vicky DiBiaso, PhD | Sanofi 

Jamie Eberling, PhD | The Michael J. Fox Foundation 

Tanya Fischer, MD, PhD | Biohaven

Alison Handler, PharmD, RPh | Novartis 

Karl Kieburtz, MD, MPH | University of Rochester 

Catherine Kopil, PhD | The Michael J. Fox Foundation 

Ken Marek, MD | Institute for Neurodegenerative Disorders 

Soania Mathur, MD | MJFF Patient Council Member 

Kalpana Merchant, PhD | TransThera Consulting 

Tom Montine, MD, PhD | Stanford University 

Karoly Nikolich, PhD | Alkahest Inc.

Gennaro Pagano, MD, PhD | Roche 

Niels Plath, PhD | Muna Therapeutics 

Kathleen Poston, MD, MS | Stanford University 

Gary Rafaloff | MJFF Patient Council Member 

Andrew Singleton, PhD | National Institutes of Health

David Stone, PhD | Cerevel Therapeutics

Bill Shrader, PhD | AcureX 

Paul Thompson, PhD | Mission Therapeutics 

Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute 

Posters
  • Poster Presentations

    Path to Prevention (P2P) Trial: Study Design and Status Update   

    Tanya Simuni, MD | Northwestern University 

     

    A Machine Learning Contest to Automatically Detect Freezing of Gait: Results and Insights 

    Jeff Hausdorff, PhD | Tel Aviv Medical Center 

     

    Aligning with Regulators to Advance Patient-Reported Outcome Assessments that are Fit-for-Purpose in Early-Stage Parkinson’s Disease Clinical Trials 

    Diane Stephenson, PhD | Critical Path Institute 

     

    The London-Dhaka Project – the Prevalence and Assessment of Cognitive Impairment in Parkinson’s Disease 

    Alastair Noyce, MSc, MRCP, PhD, FHEA | Queen Mary University of London 

     

    Hit-to-Lead STING Inhibitor Small Molecule Development for Parkinson’s Disease 

    John Streiff, PhD | AeroNeph Therapeutics 

     

    The Lysosomal Polyamine Transporter ATP13A2, an Emerging Drug Target for Parkinson’s Disease 

    Peter Vangheluwe, PhD | KU Leuven 

     

    MJFF Tools Overview  

    Nicole Polinski, PhD | MJFF 

     

    The National Plan to End Parkinson’s Act 

    Dustin Watson | MJFF

Conference Sponsors

The 15th annual Parkinson's Disease Therapeutics Conference is made possible by the support of our generous sponsors: 

Sponsor Logo Block

Interested in Sponsorship Opportunities?

View our sponsorship opportunities menu to support this year's conference.

Contact our Research Alliances team at researchpartnerships@michaeljfox.org with questions. 

About the Venue

Address

Quorum by Convene 
1221 Avenue of Americas
New York, NY 10020

Convene

 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.